文献速递类风湿关节炎

类风湿关节炎患者启用生物制剂后的恶性肿瘤风险:法国全国医疗数据库中的历史性倾向评分匹配队列研究

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
PubMed 文献 · RMD Open · 2022-01-01

经动态倾向评分匹配后,19 727例启用bDMARD者与19 727例继续csDMARD者相比,总体恶性肿瘤(HR 0.99,95%CI 0.86至1.14)、实体瘤(HR 0.95,95%CI 0.82至1.11)及淋巴瘤(HR 1.35,95%CI 0.72至2.53)风险均无统计学差异。

要点

  • 启用bDMARD与继续csDMARD的RA患者总体恶性肿瘤风险无统计学差异(HR 0.99,95%CI 0.86至1.14)。
  • 实体瘤(HR 0.95,95%CI 0.82至1.11)与淋巴瘤(HR 1.35,95%CI 0.72至2.53)风险亦无统计学差异。
  • 以TNF抑制剂为首个bDMARD者总体恶性肿瘤HR 1.03(95%CI 0.88至1.21),结果相似。

核心结论

  • 在法国全国医疗数据库的历史性队列中,启用bDMARD与继续csDMARD的RA患者总体、实体瘤及血液系统恶性肿瘤风险无显著差异。

研究设计与样本

  • 纳入无恶性肿瘤的成年RA患者,暴露自首次使用任何系统性治疗(csDMARD和/或bDMARD)开始。
  • bDMARD新使用者按动态倾向评分与继续csDMARD的患者匹配,用Cox模型比较恶性肿瘤风险。

主要发现

  • 2007年1月1日至2014年12月31日,83 706例RA患者开始首个系统性治疗,其中63 837例继续csDMARD,19 869例在随访中启用bDMARD。
  • 动态倾向评分匹配后,19 727例bDMARD启用者与19 727例继续csDMARD者进行比较。
  • 总体恶性肿瘤HR 0.99(95%CI 0.86至1.14),实体瘤HR 0.95(95%CI 0.82至1.11),淋巴瘤HR 1.35(95%CI 0.72至2.53)。
  • bDMARD单药或联合csDMARD时结果相似;以TNF抑制剂为首个bDMARD者总体恶性肿瘤HR 1.03(95%CI 0.88至1.21)。
  • 改变洗脱期(最长5年)定义风险期的敏感性分析结果相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of malignancy between patients with rheumatoid arthritis (RA) initiating their first biological disease-modifying antirheumatic drug (bDMARD) and those continuing conventional synthetic DMARDs (csDMARDs). METHODS: Nine-year historical Propensity Score (PS) matched cohort study within the French national healthcare database (87% of the French population; ~57 million people), including adults RA without malignancy. Exposures started with the first use of any systemic treatment (csDMARDs and/or bDMARDs). Incident users of bDMARDs were matched on a dynamic PS to patients continuing csDMARDs. Their risk of malignancy was compared by Cox model. RESULTS: From 1 January 2007 to 31 December 2014, 83 706 patients with RA started their first systemic treatment (63 837 remained on csDMARDs and 19 869 initiated a bDMARD during follow-up). After dynamic PS matching, 19 727 bDMARD initiators were compared with 19 727 RA remaining on csDMARDs. They did not statistically differ in risk of overall malignancies (HR 0.99 (95% CI 0.86 to 1.14)), solid cancer (HR 0.95 (95% CI 0.82 to 1.11)), nor lymphoma (HR 1.35 (95% CI 0.72 to 2.53)). Results were similar when bDMARDs were given as monotherapy or in association with csDMARDs. Analyses restricted to patients starting TNF inhibitor as first bDMARD compared with matched RA remaining on csDMARDs, provided similar results (HR for overall malignancy 1.03 (95% CI 0.88 to 1.21)). Sensitivity analyses, varying carry-over periods (up to 5 years) to define risk periods, provided similar results. CONCLUSIONS: In this historical cohort study within the French nationwide healthcare database, the risk of overall, solid or haematological malignancies did not significantly differ between patients with RA initiating bDMARD and those continuing csDMARDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Seror R, Lafourcade A, De Rycke Y, et al. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. RMD Open. 2022. PMID: 35738803. doi:10.1136/rmdopen-2021-002139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。